# Civitas Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/civitas-therapeutics

- Industry: Biotechnology
- Headquarters: Chelsea, US
- Website: www.civitastherapeutics.com
- Total disclosed funding: $111M
- Latest round: Series C (Aug 22, 2014)
- Investors on record: 12

## About

Civitas Therapeutics Inc. is focused on developing innovative therapeutic solutions aimed at addressing serious neurological diseases, utilizing advanced technologies to improve patient outcomes.Civitas Therapeutics Inc. specializes in the development of therapies for neurological disorders. Founded in 2009 and headquartered in Chelsea, US, the company was acquired by Acorda Therapeutics on September 24, 2014, for USD 525 mn. The company has successfully executed 8 deals during its operation, reflecting its strategic growth and focus in the biotechnology sector.Civitas Therapeutics offers innovative therapeutic solutions designed for patients with neurological conditions. Their primary focus is on advanced treatment methodologies that utilize proprietary drug delivery systems, ensuring effective administration of medication for improved patient outcomes. The company's offerings primarily target healthcare providers and institutions, demonstrating a commitment to enhancing the quality of life for those suffering from neurological disorders.Civitas Therapeutics operates under a revenue model that capitalizes on partnerships with healthcare organizations, providing access to its innovative therapies. This model allows for steady cash flow through long-term agreements that are often structured to include various pricing tiers based on the services offered and the scale of their application in clinical settings.With the acquisition in 2014, Civitas Therapeutics aims to leverage its expanded capabilities to enhance its product suite. The company is in the process of developing new therapeutic solutions expected to launch by 2025, targeting expansion into markets across Europe and Asia. The recent funding from the Trade Sale, amounting to USD 525 mn, will be utilized to support research and development initiatives, ensuring the advancement of new products and facilitating entry into these new geographic regions.

## Funding rounds

- Series C, Aug 22, 2014, $55M — OrbiMed Advisors, Sofinnova Investments, Canaan Partners, Bay City Capital, Adage Capital Management, Wellington Management, Longitude Capital, Fountain Healthcare Partners, RA Capital Management, Alkermes plc, Rock Springs Capital, Partner Fund Management
- Series B, Sep 11, 2013, $38M — Canaan Partners, Bay City Capital, Longitude Capital, Fountain Healthcare Partners, RA Capital Management, Alkermes plc
- Series B, Dec 19, 2012, $3.2M — Canaan Partners
- Series A, May 3, 2011, $4.3M — Canaan Partners, Longitude Capital
- Series A, Dec 27, 2010, $10M — Canaan Partners, Longitude Capital

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B, Series C
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series A, Series B, Series C
- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series B, Series C
- Fountain Healthcare Partners (https://capitalatlas.ai/funds/fountain-healthcare-partners) — Series B, Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B, Series C
- Alkermes plc — Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series C
- Adage Capital Management — Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series C
- Rock Springs Capital — Series C
- Partner Fund Management — Series C